about
Perfusion MRI: the five most frequently asked clinical questions.Perfusion MRI: the five most frequently asked technical questionsOptimizing contrast-enhanced magnetic resonance imaging characterization of brain metastases: relevance to stereotactic radiosurgery.Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): the first case with a combination of 'not common' variants.Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging.Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software.Neuroradiologic differential diagnosis of cerebral intraparenchymal hemorrhage.Contrast-enhanced MRA of intracranial vessels.High relaxivity contrast agents in MR angiography of the carotid arteries.Contribution of magnetic resonance imaging to the diagnosis and monitoring of multiple sclerosis.Three dimensional time-of-flight magnetic resonance angiography in carotid artery surgery: a comparison with digital subtraction angiography.Comparison of 3D TOF-MRA and 3D CE-MRA at 3T for imaging of intracranial aneurysms.Gadobutrol in India-A Comprehensive Review of Safety and Efficacy.Relation between characteristics of carotid atherosclerotic plaques and brain white matter hyperintensities in asymptomatic patientsComparative studies of different gadolinium agents in brain tumors: differences between gadolinium chelates and their possible influence on imaging features.Post-traumatic interpeduncular cistern hemorrhage as a marker for brainstem lesions.Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine.Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images.Early prognosis after severe traumatic brain injury with minor or absent computed tomography scan lesions.Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.18F-FAZA PET/CT Hypoxia Imaging of High-Grade Glioma Before and After Radiotherapy.Cerebrospinal Fluid Analysis in Immunoglobulin G4-related Hypertrophic PachymeningitisFollow-up of Coiled Cerebral Aneurysms: Comparison of Three-Dimensional Time-of-Flight Magnetic Resonance Angiography at 3 Tesla With Three-Dimensional Time-of-Flight Magnetic Resonance Angiography and Contrast-Enhanced Magnetic Resonance AngiographyLacunar infarction in a puerpera with mitral valve prolapse.Cerebral fat embolism, brain swelling, and severe intracranial hypertension.Vertebral artery dissection: looking for the ideal study protocolMR angiography follow-up of aneurysms treated with coils: is there a need for the use of gadolinium?R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphomaComparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomasMultifocal laminar cortical brain lesions: a consistent MRI finding in neuro-COVID-19 patientsSubstantia Nigra Volumetry with 3-T MRI in De Novo and Advanced Parkinson Disease
P50
Q30416198-75335813-1452-4185-920D-F22E40A8B098Q30421969-098FA444-EB37-47F2-9E53-376FA238139BQ30586979-02942CB4-9532-4D55-B63D-7141D668C70CQ30745219-43B764C1-C87B-4F1D-87EB-0AA407115E3CQ30818733-7C90F9C1-8263-49F5-BE46-94919C46A9BFQ31153877-6E889711-9159-42C7-B5B8-CA054DE81043Q33200258-0E7544E6-8DDF-4A5B-B5C2-86C800D6C0E3Q37219778-6D6FD896-06C4-4BA1-B272-D0166AAAAFE0Q37226731-9E7C42D2-9832-4EAA-A4A8-9AC8A23FCF5DQ37995056-04880D91-2D0E-4B36-9544-776772FFC611Q39413354-F7C3EB26-4C4E-4AB3-8C59-6B76CB7FCCE5Q40142104-10F79594-01C2-45BB-8086-FA1259222528Q41078976-BE8B05FD-2E4D-4B91-9144-83ABEE60C4E6Q41621079-E68E927F-80EA-4A8D-9B9C-5613C4F3B0F6Q43124662-3B69F7C5-1AD8-44B8-9182-0DA77FE7B102Q43431482-D3FF5EA2-16A3-466F-8811-C40B4D6DA552Q45922459-458C9CAF-EACE-4C51-BA8F-C213F491FBCDQ47357272-454BF5AB-81B8-4698-8E86-A471D590714AQ47844664-B9029828-BB65-475D-BD23-8CA5B64AFA77Q48288302-7768EC1A-8256-440C-813D-DD3FAD2AE66AQ48752617-B8A54848-BC83-4164-A593-303173F802EDQ50073906-984A6C55-B4C6-4F30-82E7-0E3CC55DA21DQ57267903-FF8CE28C-3575-48FC-8ACE-A443ACD108C4Q60332546-E727E8A0-142C-4413-A80B-C03110822261Q64905779-B87F831E-E9D5-486F-B2FE-12F000E53840Q64984572-873ABC93-27F3-4347-B6D0-655FF816F6BCQ83808844-4015C9BC-D7B2-4D10-94F0-E187CAA1FBE6Q84162403-F8682D87-962B-4F76-9AB6-249189D5F741Q92225238-8ED989D2-D8F9-453E-B532-CB37E5389268Q93016709-D7D14981-F1A5-4A76-B1FE-E20BF364DB8DQ96162514-527ADB8E-4583-4228-B043-333B5C94C761Q96437062-48A67755-C8FA-43AA-9867-7CF10DC3B590
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicoletta Anzalone
@ast
Nicoletta Anzalone
@en
Nicoletta Anzalone
@es
Nicoletta Anzalone
@nl
type
label
Nicoletta Anzalone
@ast
Nicoletta Anzalone
@en
Nicoletta Anzalone
@es
Nicoletta Anzalone
@nl
prefLabel
Nicoletta Anzalone
@ast
Nicoletta Anzalone
@en
Nicoletta Anzalone
@es
Nicoletta Anzalone
@nl
P106
P1153
6603802056
P31
P496
0000-0002-4249-2723